CSF2 and neoplasm: Although the combination therapy with PD-1 blockade and the SA-GM-CSF-anchored vaccine induced a better antitumor immune response than PD-1 blockade or the SA-GM-CSF-anchored vaccine alone, some of the mice still exhibited eventual tumor progression, the tumor regression rate was too low (20% regression).